Rubfila International Ltd (RUBFILA)

Fast Moving Consumer Goods · Plantation & Plantation Products · NSE · Updated 17 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹66 ↓ 23.33% (1Y)

🎯 Key Takeaways

Rubfila International Ltd is undergoing a strategic simplification phase, exiting non-core subsidiary Premier Tissues (India) Limited through a planned divestment while consolidating focus on its core rubber-thread manufacturing business. The company maintains a debt-free balance sheet and stable profitability, but faces headwinds from declining revenue trends and governance concerns around provisioning irregularities.
Revenue declined 16.9% QoQ to ₹133 in Q1FY27.
⚠️ 1) The overstated provision of ₹1,379 lakhs and inability to verify an accumulated balance of ₹1,349 lakhs raise concerns about accounting compliance

Market Cap

₹358

P/E Ratio

13.6

P/B Ratio

1.22

ROE

8.8%

ROCE

12.3%

Debt/Equity

0.00

Div Yield

3.03%

Promoter

58.5%

✨ Ask AI About RUBFILA 📊 Interactive Charts

📖 The Story

Rubfila International Ltd is undergoing a strategic simplification phase, exiting non-core subsidiary Premier Tissues (India) Limited through a planned divestment while consolidating focus on its core rubber-thread manufacturing business. The company maintains a debt-free balance sheet and stable profitability, but faces headwinds from declining revenue trends and governance concerns around provisioning irregularities.

📰 What's Happening

The company announced in August 2026 its board-approved divestment of the entire stake in Premier Tissues (India) Limited to Finquest Personal Care Pvt Ltd for €61.00 crore, with transaction documents to be executed by 10-09-2026 and payment due within 30 days of approvals. The 33rd AGM is scheduled for 29th September 2026. Concurrently, Non-Executive Director Bharat J Dattani resigned effective 6th July 2026, accepted by the Non-Executive Chairman on 16th July 2026. Management also highlighted robust compliance systems, with the Compliance Officer certifying adherence to SEBI insider trading norms via a Structured Digital Database capturing all UPSI events in Q1 FY2026.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	150	147	161	133
Operating Profit	8	6	8	6
OPM %	5.5%	4.0%	5.1%	4.8%
Net Profit	8	6	6	6
EPS	₹1.47	₹1.01	₹1.31	₹1.07

Quarterly revenue has declined sequentially from ₹150 crores in September 2025 to ₹133 crores in June 2026, with operating profit margin compressing from 5.5% to 4.8% over the same period. Despite stable net profit of ₹6 crores in the last two quarters, EPS has dipped from ₹1.47 to ₹1.07, reflecting margin pressure and potential provisioning adjustments. The company disclosed in July 2026 that consolidated PBT for Q1 FY2026 was overstated by ₹30 lakhs due to an overstated provision of ₹1,379 lakhs, primarily linked to an unverifyable accumulated balance of ₹1,349 lakhs, raising concerns about compliance with Ind AS 37 and SEBI disclosure norms.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or profitability in the reviewed filings, but the divestment of Premier Tissues is framed as a strategic move to unlock value for the core rubber-thread business. The board has scheduled the 33rd AGM for 29th September 2026 to seek shareholder approval for the transaction, with management indicating that the sale will facilitate capital allocation to the core business. No commentary on future margins or growth was included in the latest disclosures.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2026	Mar 2026	Mar 2026	Mar 2027
Equity Capital	27	27	27	27	27
Reserves	267	271	276	283	289
Borrowings	0	1	1	1	1
Total Liabilities	358	363	364	379	381
Fixed Assets	165	167	168	169	169
Investments	0	0	0	0	0
Total Assets	358	363	364	379	381

The balance sheet remains exceptionally conservative, with total assets of ₹381 crores as of March 2027 comprising just ₹27 crores in equity and reserves, and ₹1 crore in borrowings. This reflects a debt-free capital structure and minimal asset base, consistent with a mature plantation and rubber-thread business. The stability in equity and reserves over recent periods suggests limited reinvestment or capital return activity, with no significant changes in asset or liability levels reported.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+25
Investing	-7
Financing	-7
Net Cash Flow	+11

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	57.8%	57.8%	58.3%	58.5%
FII	0.2%	0.1%	0.0%	0.0%
DII	0.0%	0.0%	0.0%	0.0%
Public	32.3%	32.1%	31.4%	30.5%
# Shareholders	39,725	38,346	37,654	36,905

Promoter holding has gradually increased from 57.77% in Q2FY26 to 58.47% in Q1FY27, indicating confidence from the promoter group. Institutional ownership remains negligible, with FII and DII holdings flatlined at 0.01% and 0% respectively over the past year. The number of public shareholders has slightly declined from 39,725 to 36,905, suggesting possible consolidation in retail ownership. No pledging or sale signals have emerged from promoter or institutional levels.

⚖️ Peer Comparison — Plantation & Plantation Products

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
CCL	14,223	32.8	16.4%	22.0%	0.92
PIXTRANS	2,347	17.8	24.8%	18.9%	0.03
TINNARUBR	1,801	28.7	30.3%	34.6%	0.75
GRPLTD	1,047	184.6	7.4%	3.2%	1.16
523888	532	47.7	-301224.5%	-415.1%	-1.00
INTLCONV	480	3.5	40.2%	37.6%	0.24
GOODRICKE	469	7.4	21.3%	20.8%	0.04
MCLEODRUSS	446	—	-10.5%	-164.9%	33.57
RUBFILA	358	13.6	12.3%	8.8%	0.00
HARRMALAYA	338	12.5	13.8%	15.2%	0.60

🔗 Peer Stock Analyses

CCL PIXTRANS TINNARUBR GRPLTD 523888

⚠️ Risk Factors

1) The overstated provision of ₹1,379 lakhs and inability to verify an accumulated balance of ₹1,349 lakhs raise concerns about accounting compliance and potential regulatory scrutiny under Ind AS 37 and SEBI norms. 2) Declining quarterly revenue and compressing operating margins indicate weakening core business momentum, with no clear growth catalyst disclosed. 3) The divestment of Premier Tissues, while strategic, introduces execution and regulatory risk given the need for shareholder and regulatory approvals, with payment contingent on timely closure.

📋 Recent Filings

🧠 Analyst's Read

Rubfila is in a transitional phase marked by strategic simplification and governance scrutiny, with financial performance under pressure from margin compression and revenue decline. Investors should monitor the timely execution of the Premier Tissues divestment and the company's ability to address the provisioning concerns raised by the board, as these will be critical to restoring confidence and clarifying the path forward for the core business.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on RUBFILA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when RUBFILA files new disclosures

Track RUBFILA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RUBFILA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd